- Application under evaluation
- CVMP opinion
- European Commission decision
Overview
The marketing authorisation for Slentrol has been withdrawn at the request of the marketing authorisation holder.
Slentrol : EPAR - Summary for the public
English (EN) (217.43 KB - PDF)
български (BG) (279.69 KB - PDF)
español (ES) (239.85 KB - PDF)
čeština (CS) (283.94 KB - PDF)
dansk (DA) (239 KB - PDF)
Deutsch (DE) (241.8 KB - PDF)
eesti keel (ET) (237.14 KB - PDF)
ελληνικά (EL) (282.67 KB - PDF)
français (FR) (245.68 KB - PDF)
italiano (IT) (238.08 KB - PDF)
latviešu valoda (LV) (283.06 KB - PDF)
lietuvių kalba (LT) (251.47 KB - PDF)
magyar (HU) (253.42 KB - PDF)
Malti (MT) (265.77 KB - PDF)
Nederlands (NL) (217.72 KB - PDF)
polski (PL) (282.55 KB - PDF)
português (PT) (218.29 KB - PDF)
română (RO) (242.81 KB - PDF)
slovenčina (SK) (260.4 KB - PDF)
slovenščina (SL) (252.65 KB - PDF)
Suomi (FI) (237.94 KB - PDF)
svenska (SV) (239.22 KB - PDF)
Product information
Slentrol : EPAR - Product Information
English (EN) (420.64 KB - PDF)
български (BG) (1.12 MB - PDF)
español (ES) (413.23 KB - PDF)
čeština (CS) (559.01 KB - PDF)
dansk (DA) (619.26 KB - PDF)
Deutsch (DE) (409.78 KB - PDF)
eesti keel (ET) (394.94 KB - PDF)
ελληνικά (EL) (1.78 MB - PDF)
français (FR) (455.26 KB - PDF)
íslenska (IS) (418.64 KB - PDF)
italiano (IT) (432.39 KB - PDF)
latviešu valoda (LV) (543.86 KB - PDF)
lietuvių kalba (LT) (475.04 KB - PDF)
magyar (HU) (577.53 KB - PDF)
Malti (MT) (631.26 KB - PDF)
Nederlands (NL) (419.67 KB - PDF)
norsk (NO) (405.73 KB - PDF)
polski (PL) (601.64 KB - PDF)
português (PT) (402.62 KB - PDF)
română (RO) (490.98 KB - PDF)
slovenčina (SK) (616.03 KB - PDF)
slovenščina (SL) (568.91 KB - PDF)
Suomi (FI) (408.3 KB - PDF)
svenska (SV) (413.86 KB - PDF)
Slentrol : EPAR - All Authorised presentations
English (EN) (148.01 KB - PDF)
български (BG) (202.54 KB - PDF)
español (ES) (148.22 KB - PDF)
čeština (CS) (192.56 KB - PDF)
dansk (DA) (151.57 KB - PDF)
Deutsch (DE) (152.17 KB - PDF)
eesti keel (ET) (147.88 KB - PDF)
ελληνικά (EL) (200.73 KB - PDF)
français (FR) (474.14 KB - PDF)
íslenska (IS) (151.76 KB - PDF)
italiano (IT) (148.51 KB - PDF)
latviešu valoda (LV) (202.11 KB - PDF)
lietuvių kalba (LT) (191.42 KB - PDF)
magyar (HU) (188.69 KB - PDF)
Malti (MT) (194.75 KB - PDF)
Nederlands (NL) (151.46 KB - PDF)
norsk (NO) (148.31 KB - PDF)
polski (PL) (176.01 KB - PDF)
português (PT) (151.81 KB - PDF)
română (RO) (188.05 KB - PDF)
slovenčina (SK) (195.92 KB - PDF)
slovenščina (SL) (189.87 KB - PDF)
Suomi (FI) (147.96 KB - PDF)
svenska (SV) (151.54 KB - PDF)
Product details
- Name of medicine
- Slentrol
- Active substance
- dirlotapide
- International non-proprietary name (INN) or common name
- dirlotapide
- Species
- Dogs
- Anatomical therapeutic chemical veterinary (ATCvet) code
- QA08AB91
Pharmacotherapeutic group
Antiobesity preparations, excl. diet productsTherapeutic indication
As an aid in the management of overweight and obesity in adult dogs. To be used as part of an overall weight-management programme that also includes appropriate dietary changes and exercise practice.
Authorisation details
- EMA product number
- EMEA/V/C/000116
- Marketing authorisation holder
- Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium - Marketing authorisation issued
- 13/04/2007
- Revision
- 7
Assessment history
Slentrol : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (203.02 KB - PDF)